Antihypertensive Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta Blockers, Alpha Blockers, Renin Inhibitors, Calcium Channel Blockers, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Antihypertensive Drugs Market Size

The global antihypertensive drugs market size was valued at USD 22.60 Billion in 2023 and is projected to reach USD 33.49 Billion by 2032, growing at a CAGR of 3.87% during the forecast period (2024–2032).

The antihypertensive drug market refers to economic activity related to drugs used to treat high blood pressure. This market includes the research, development, production, distribution and sale of these drugs. These medications come in different forms, including pills, capsules, and liquids. Antihypertensive drugs work through different mechanisms by relaxing blood vessels, reducing the amount of fluid in the body or slowing the heart rate, all to lower blood pressure and prevent serious health problems.

The global antihypertensive drugs market is fuelled by the increasing incidence of hypertension, aging population and growing public awareness of cardiovascular diseases. The increase comes as huge numbers of people struggle with uncontrolled high blood pressure, a silent killer that greatly increases the risk of heart attack, stroke and kidney failure. The need for efficient medications to treat high blood pressure is predicted to increase as the global population ages and lifestyle choices exacerbate the condition. Growing public health campaigns and education programs that highlight the risks of uncontrolled hypertension contribute to further this trend. The market for blood pressure medications is looking positive due to this confluence of factors, and growth is expected to continue in the future.

Antihypertensive Drugs Market Growth Factors

Rising prevalence of hypertension

The prevalence of hypertension is increasing rapidly worldwide. An aging population and an increase in the number of people following unhealthy lifestyles are two of the main factors behind this trend. Their arteries naturally become less elastic with age, making it harder for the heart to pump blood efficiently. For instance, the Centers for Disease Control and Prevention estimate that in July 2022, 116 million individuals, or 47 percent of the adult population, will have hypertension. Therefore, it is anticipated that as the prevalence of hypertension rises, so will the need for antihypertensive medications, propelling the market's expansion.

Growing awareness and public initiatives

Public health initiatives and campaigns are playing a crucial role by educating the public about the dangers of high blood pressure and the importance of regular checkups, these efforts are leading to more diagnoses. For instance, in November 2021, New public service announcements (PSAs) were released by the American Heart Association (AHA), American Medical Association (AMA), HHS Office of Minority Health (OMH), Health Resources & Services Administration (HRSA), and the Ad Council to encourage people to take charge of their health by self-monitoring their blood pressure and talking with a healthcare provider about their numbers.

Market Restraining Factors

Increasing product recalls

In the antihypertensive drugs market, there may be a rise in product recalls. Patients may become less confident and reluctant to begin or continue taking their prescription as a result of these recalls, which are frequently brought on by impurities or adverse effects. For the time being, this might hinder market expansion. For instance, in March 2022, Pfizer Inc. voluntarily recalled lots of ACCURETIC (quinapril HCl/hydrochlorothiazide), quinapril and hydrochlorothiazide Tablets, and quinapril HCl/hydrochlorothiazide tablets due to N-Nitroso- Quinapril content, which is elevated levels of a potentially cancer-causing impurity.

Market Opportunities

Digital therapeutics and remote monitoring

The antihypertensive drugs market has a disruptive opportunity thanks to digital medicine and remote monitoring. Patients can benefit from features such as prescription reminders, easy blood pressure monitoring with connected devices and remote consultations with healthcare professionals by creating apps or digital tools. This gives patients more choices about how they manage their health, which can lead to better compliance, more effective blood pressure control, and lower medical costs. Furthermore, by expanding the scope of care beyond conventional clinic visits, these technologies can improve accessibility and convenience in a larger patient community.

Expanding market access through generic drugs and strategic launches

Expanding market access for hypertension treatment is crucial. Generic antihypertensive drugs offer a solution. These affordable alternatives to brand-name medications, strategically launched, can significantly increase access. For instance, in December 2021, Dr Reddy's Laboratories launched Valsartan tablets, used for the treatment of high blood pressure and heart failure, in the United States market. The Valsartan tablet is the generic therapeutic equivalent of Diovan, approved by the United States Food and Drug Administration (USFDA). By strategically launching generic antihypertensives, pharmaceutical companies can ensure wider patient access to effective treatments, contributing to improved public health outcomes and a more sustainable healthcare system.

Regional Insights

North America is the most significant global market shareholder and is expected to expand substantially during the forecast period. Some of the major factors driving the North American anti-hypertension market are the demand for rapid and precise hypertension diagnosis and treatment, the need to identify individuals who are predisposed to the condition, the availability of technologically advanced healthcare facilities, and the demand to manage the prognosis of the condition.

• U.S. antihypertensive drugs market. Patent expirations for brand-name drugs are leading to increased generic competition and a shift towards more cost-effective treatment options. This trend, alongside the growing focus on combination therapies, is expected to shape the future of the U.S. antihypertensive landscape.
• Canada antihypertensive drugs market. A stronger emphasis on public health initiatives and generic drug access programs to ensure affordability for patients is driving the growth of Canada’s market.

Thus, the factors above are estimated to boost the North America antihypertensive drugs market growth.

Asia-Pacific region is a pivotal market for the arthroscopic shaver industry. A large and growing population with high hypertension rates, especially in China and India, fuels this growth. An aging population and rising heart disease further drive demand, while increasing cost-consciousness paves the way for affordable generics.

• The China antihypertensive drugs market. With a massive population and a high prevalence of hypertension. However, challenges like affordability and low treatment adherence highlight the need for strategic launches of cost-effective generics alongside public health initiatives to improve overall hypertension management in China.
• The India antihypertensive drugs market. A large and growing population, coupled with a high prevalence of hypertension, creates a massive demand for treatment. Strategic drug launches and collaborations aim to expand the geographical reach and provide solutions is propelling the market growth.

These factors are estimated to drive the Asia Pacific antihypertensive drugs market growth.

Antihypertensive Drugs Market Segmentation Analysis

By therapeutic class

The market is segmented into opioids and non-opioids. Diuretics dominate the drug class segment. This is because they are an established and cost-effective first-line treatment for hypertension. They have a rapid blood pressure-lowering effect and are often included in combination therapy.

By distribution channel

The market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies dominate the distribution channel segment. This dominance is due to the wider range of medications they stock, including specialized and investigational drugs for patients requiring closer monitoring or specific treatment plans.

Recent Developments

• In March 2024, Idorsia Pharmaceuticals U.S. Inc. announced the US Food and Drug Administration (FDA) had approved TRYVIO (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs.
• In December 2023, Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, announced the first subject had been dosed in the Launch-HTN (NCT06153693) pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to prescribed background treatment.
• In November 2021, Baxter International Inc., a global leader in sterile medication production and delivery, announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine). Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure).

Analyst’s Perspective

According to analysts, focusing on generics and making strategic launches as a two-pronged strategy to successfully navigate the global antihypertensive market. Because generic medications are more affordable, more patients in cost-conscious areas may get them. Reach may be further increased by strategic launches, particularly those that focus on underserved areas and utilize the partnerships with local healthcare professionals. This strategy ensures more patients' access to efficient treatments, improving public health outcomes and building a more resilient healthcare system.